New HIV vaccine candidate passes early safety check in small trial
NCT ID NCT05828095
First seen Nov 01, 2025 · Last updated May 12, 2026 · Updated 27 times
Summary
This early-stage study tested a new HIV vaccine called INO-6160 in 20 healthy adults without HIV. The vaccine uses synthetic DNA to teach the body to recognize HIV and includes an immune booster (IL-12). Some participants also received a booster shot with a different HIV protein. The main goals were to check safety and see if the vaccine triggers an immune response. Results will help design larger studies toward an effective HIV vaccine.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HIV-1-INFECTION are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
New York Blood Center CRS
New York, New York, 10065, United States
-
Penn Prevention CRS
Philadelphia, Pennsylvania, 19104, United States
-
Vanderbuilt Vaccine (VV) CRS
Nashville, Tennessee, 37232, United States
Conditions
Explore the condition pages connected to this study.